- Conditions
- Crohn's Disease
- Interventions
- Vedolizumab, Adalimumab, Ustekinumab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 41
- States / cities
- Dothan, Alabama • Sun City, Arizona • La Jolla, California + 37 more
Location Directory
Clinical trials in San Antonio, Texas
This page shows live ClinicalTrials.gov search results for San Antonio, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
3151
Shown on this page
12
Current sort
Recently updated
Location scope
San Antonio, TX
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 121–132 of 3,151 matching trials in San Antonio, TX.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Breast Cancer
- Interventions
- TOL2506, Tamoxifen, Letrozole tablets, Anastrozole Tablets, Exemestane Tablets
- Drug
- Lead sponsor
- Tolmar Inc.
- Industry
- Eligibility
- 18 Years to 51 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 17
- States / cities
- Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more
- Conditions
- Hepatic Impairment
- Interventions
- Inavolisib
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Lake Forest, California • Orlando, Florida • San Antonio, Texas
- Conditions
- Advanced Solid Tumor
- Interventions
- GS-5319, Carboplatin, Pemetrexed, Pembrolizumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 476 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New Brunswick, New Jersey • San Antonio, Texas + 1 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Sonrotoclax, Obinutuzumab, Rituximab, Venetoclax
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 39
- States / cities
- Laguna Hills, California • Orange, California • Palo Alto, California + 35 more
- Conditions
- Breast Cancer
- Interventions
- anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,939 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 1454
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 888 more
- Conditions
- Untreated, Unresectable, or Metastatic Colorectal Cancer
- Interventions
- Pumitamig, FOLFOX, FOLFIRI, Bevacizumab, CAPOX
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 46
- States / cities
- Tucson, Arizona • Springdale, Arkansas • Los Angeles, California + 40 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Elritercept, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 25
- States / cities
- Duarte, California • Glendale, California • La Jolla, California + 21 more
- Conditions
- Breast Cancer
- Interventions
- TOL2506, Tamoxifen, Letrozole Tablets, Anastrozole Tablets, Exemestane Tablets
- Drug
- Lead sponsor
- Tolmar Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 17
- States / cities
- Greenbrae, California • Parker, Colorado • Chicago, Illinois + 14 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Pumitamig, Pembrolizumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 41
- States / cities
- Daphne, Alabama • Bullhead City, Arizona • Glendale, Arizona + 37 more
- Conditions
- High-risk Non-muscle Invasive Bladder Cancer
- Interventions
- Pembrolizumab, BCG
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2034
- U.S. locations
- 44
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 39 more
- Conditions
- Chemotherapy-induced Thrombocytopenia
- Interventions
- Romiplostim, Placebo
- Biological · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 22
- States / cities
- Jonesboro, Arkansas • Anaheim, California • Orange, California + 18 more